In another blow to big pharma, India's Supreme Court rejects Novartis's Glivec patent plea

India’s Supreme Court has issued its eagerly anticipated judgment in the long-running Glivec patent case. Upholding previous decisions, the court ruled that the country’s patent office was right to refuse a patent to Novartis for its anti-cancer…

Get unlimited access to all IAM content